The Chicago-based investment bank owned more than 3.8 million NXTM shares as of Dec. 31, 2012, up 19.5% from the 3.2 million shares it owned at the close of 2011.
That amounts to a 6.5% stake in Lawrence, Mass.-based NxStage, which makes home hemodialysis equipment.
Covidien’s Mallinckrodt pharma spinout will list on NYSE
Covidien (NYSE:COV) said the spinout of its pharmaceuticals business, Mallinckrodt, will list on the New York Stock Exchange under the MNK symbol. The spinout is expected to take effect some time in the middle of 2013.
Echo Therapeutics offering tops $10M
Echo Therapeutics (NSDQ:ECTE) grossed $10.2 million from a public offering of more than 13.6 million shares of its common stock at 75¢ apiece.
The Philadelphia-based medical device company plans to use some of the cash to pay down debt and for "general corporate purposes."
- Cyberonics (NSDQ:CYBX): Piper Jaffray reiterates "overweight" rating, $55 price target.
- Edwards Lifesciences (NYSE:EW): Canaccord Genuity reiterates "buy" rating, raises price target from $109 to $115; Leerink Swann reiterates "outperform" rating, $100 price target.
- Hologic (NSDQ:HOLX): Leerink Swann increases price target to $28 from $25, maintains "outperform" rating.
- St. Jude Medical (NYSE:STJ): Mizuho Securities raises price target to $48 from $46.